BioFactura Awarded $67.4 Million Advanced Development Contract for its Smallpox Biodefense Therapeutic
Frederick, Maryland, September 26, 2019: BioFactura, Inc. today announced a contract awarded by the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $67.4 million for the advanced development of its Smallpox Biodefense Therapeutic as a potential medical countermeasure (MCM) for the treatment of smallpox. This product has the potential to fulfill an … Continue reading